Literature DB >> 27459541

Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability.

Matthew J Sikora1, Michael D Johnson1, Adrian V Lee1, Steffi Oesterreich1.   

Abstract

Charcoal-stripped bovine serum (CSS) is a critical reagent in the study of steroid hormones. However, CSS has high lot-to-lot variability, including residual growth factor and steroid hormone content. Assessing and reporting this variability is challenging but may affect experimental outcomes and data reproducibility. We hypothesized that CSS lot variability would affect endocrine response phenotypes in breast cancer cells, and we tested the effects of five individual CSS lots on endocrine response in MCF-7 and MDA MB 134VI (MM134) cells. Based on the effects of antiestrogens on MCF-7 cell proliferation, we defined CSS lots as having complete vs partial hormone deprivation. In partial deprivation CSS, the absolute effects of residual estrogens on cell proliferation were modest, but these effects masked the partial agonist activity of 4-hydroxytamoxifen in MM134 cells. Importantly, this effectively reversed the interpretation of tamoxifen-resistance in MM134 cells. Variable effects of CSS lots on endocrine resistance phenotypes were also observed in MCF-7 cells. In this context, we observed that partial vs complete deprivation CSS allowed for the development of unique early endocrine resistance phenotypes that correlated with the presence or absence of residual estrogenic hormones. We evaluated the methods of CSS preparation and identified factors contributing to the extent of hormone deprivation. Our observations suggest that CSS lot-to-lot variability has substantial effects on endocrine response phenotypes and that this ubiquitous factor in study methodology may confound reproducibility. Renewed vigilance in testing and reporting CSS phenotypes will greatly aid in interpreting and reproducing endocrine response and resistance data by the community.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27459541      PMCID: PMC5045515          DOI: 10.1210/en.2016-1297

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

1.  Estrogenic impurities in labware.

Authors:  T Ishikawa; K Takano; J Yasufuku-Takano; T Fujita; T Igarashi; M Miura; K Hata
Journal:  Nat Biotechnol       Date:  2001-09       Impact factor: 54.908

Review 2.  On the disruption of biochemical and biological assays by chemicals leaching from disposable laboratory plasticware.

Authors:  Aldo Olivieri; Owen S Degenhardt; G Reid McDonald; Deepak Narang; Isabelle M Paulsen; Janna L Kozuska; Andrew Holt
Journal:  Can J Physiol Pharmacol       Date:  2012-04-17       Impact factor: 2.273

Review 3.  Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.

Authors:  Qingqing Wang; Lisa Bottalico; Clementina Mesaros; Ian A Blair
Journal:  Steroids       Date:  2014-08-20       Impact factor: 2.668

4.  Bioactive contaminants leach from disposable laboratory plasticware.

Authors:  G Reid McDonald; Alan L Hudson; Susan M J Dunn; Haitao You; Glen B Baker; Randy M Whittal; Jonathan W Martin; Amitabh Jha; Dale E Edmondson; Andrew Holt
Journal:  Science       Date:  2008-11-07       Impact factor: 47.728

Review 5.  Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.

Authors:  A V Lee; X Cui; S Oesterreich
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

6.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

7.  Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells.

Authors:  R L Eckert; B S Katzenellenbogen
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

8.  27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.

Authors:  Carolyn D DuSell; Michihisa Umetani; Philip W Shaul; David J Mangelsdorf; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2007-09-13

9.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Authors:  Matthew J Sikora; Kristine L Cooper; Amir Bahreini; Soumya Luthra; Guoying Wang; Uma R Chandran; Nancy E Davidson; David J Dabbs; Alana L Welm; Steffi Oesterreich
Journal:  Cancer Res       Date:  2014-01-14       Impact factor: 12.701

10.  The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

Authors:  Matthew J Sikora; Kevin E Cordero; Jose M Larios; Michael D Johnson; Marc E Lippman; James M Rae
Journal:  Breast Cancer Res Treat       Date:  2008-06-04       Impact factor: 4.872

View more
  17 in total

Review 1.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

2.  Reproducibility: Respect your cells!

Authors:  Monya Baker
Journal:  Nature       Date:  2016-09-15       Impact factor: 49.962

3.  Ethical Challenges Using Human Tumor Cell Lines in Cancer Research.

Authors:  Wilhelm G Dirks
Journal:  Recent Results Cancer Res       Date:  2021

4.  Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer.

Authors:  Matthew W Boudreau; Michael P Mulligan; David J Shapiro; Timothy M Fan; Paul J Hergenrother
Journal:  J Med Chem       Date:  2022-01-26       Impact factor: 8.039

5.  Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.

Authors:  Sreeja Sreekumar; Kevin M Levine; Matthew J Sikora; Jian Chen; Nilgun Tasdemir; Dorothy Carter; David J Dabbs; Carolin Meier; Ahmed Basudan; David Boone; Priscilla F McAuliffe; Rachel C Jankowitz; Adrian V Lee; Jennifer M Atkinson; Steffi Oesterreich
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

6.  Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.

Authors:  Joseph L Sottnik; Evelyn K Bordeaux; Sanjana Mehrotra; Sarah E Ferrara; Andrew E Goodspeed; James C Costello; Matthew J Sikora
Journal:  Mol Cancer Res       Date:  2021-05-04       Impact factor: 5.852

7.  ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.

Authors:  Zheqi Li; Olivia McGinn; Yang Wu; Amir Bahreini; Nolan M Priedigkeit; Kai Ding; Sayali Onkar; Caleb Lampenfeld; Carol A Sartorius; Lori Miller; Margaret Rosenzweig; Ofir Cohen; Nikhil Wagle; Jennifer K Richer; William J Muller; Laki Buluwela; Simak Ali; Tullia C Bruno; Dario A A Vignali; Yusi Fang; Li Zhu; George C Tseng; Jason Gertz; Jennifer M Atkinson; Adrian V Lee; Steffi Oesterreich
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

8.  Fatty acids rather than hormones restore in vitro angiogenesis in human male and female endothelial cells cultured in charcoal-stripped serum.

Authors:  Claudia Vanetti; Francesco Bifari; Lucia M Vicentini; Maria Grazia Cattaneo
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

9.  Estradiol Regulates mRNA Levels of Estrogen Receptor Beta 4 and Beta 5 Isoforms and Modulates Human Granulosa Cell Apoptosis.

Authors:  Alice Pierre; Anne Mayeur; Clémentine Marie; Victoria Cluzet; Jonathan Chauvin; Nelly Frydman; Michael Grynberg; Joelle Cohen-Tannoudji; Céline J Guigon; Stéphanie Chauvin
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

10.  WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.

Authors:  Matthew J Sikora; Britta M Jacobsen; Kevin Levine; Jian Chen; Nancy E Davidson; Adrian V Lee; Caroline M Alexander; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2016-09-20       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.